Nvwm LLC Reduces Holdings in Zoetis Inc. $ZTS

Nvwm LLC decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 14.3% in the 2nd quarter, Holdings Channel reports. The fund owned 13,470 shares of the company’s stock after selling 2,244 shares during the quarter. Nvwm LLC’s holdings in Zoetis were worth $2,101,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in ZTS. Lindbrook Capital LLC increased its stake in shares of Zoetis by 1.8% in the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock worth $612,000 after purchasing an additional 65 shares in the last quarter. Scott & Selber Inc. boosted its holdings in Zoetis by 0.6% in the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock worth $1,817,000 after buying an additional 67 shares during the period. Secure Asset Management LLC grew its stake in Zoetis by 2.9% in the 2nd quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock valued at $382,000 after buying an additional 68 shares in the last quarter. Quotient Wealth Partners LLC raised its holdings in Zoetis by 2.3% during the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company’s stock valued at $521,000 after acquiring an additional 72 shares during the period. Finally, Moment Partners LLC lifted its position in shares of Zoetis by 3.2% during the second quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock worth $367,000 after acquiring an additional 72 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

ZTS opened at $119.81 on Friday. The stock has a market capitalization of $53.10 billion, a P/E ratio of 20.62, a PEG ratio of 2.31 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12-month low of $119.06 and a 12-month high of $181.85. The stock has a 50-day moving average price of $144.93 and a 200-day moving average price of $152.78.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s revenue was up .5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is presently 33.67%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ZTS. Stifel Nicolaus set a $140.00 price objective on Zoetis in a research note on Tuesday. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. UBS Group cut their price objective on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research report on Wednesday. Piper Sandler upped their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Finally, Argus reissued a “buy” rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Five investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $191.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.